Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
RQ Bio has closed a $115m Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups.
Faced with slow-moving study endpoints and distant clinical thresholds, nephrology sponsors need earlier insights to support critical development decisions.
Genprex has received a Notice of Allowance from the CIPO for a patent related to the use of its Reqorsa gene therapy in combination with either PD-1 or PD-L1 antibodies to treat NSCLC and SCLC.
The Office of the US Trade Representative (USTR) has triggered a new active investigation targeting Germany over what it describes as "persistent underpayment for innovative medicines” and other policies discriminatory to US commerce.
We explore the ADC market’s evolution, the unique challenges of packaging ADCs, and how strategic collaborations can help companies navigate future trends and requirements.
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked TCE therapeutics
At ADA 2026, findings from the Phase III TRIUMPH-1 trial were presented, assessing Eli Lilly's retatrutide in adults with obesity or overweight and at least one weight-related comorbidity.
Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of TCE multispecific antibodies for GI cancers and other solid tumours.
LG AI Research and D&D Pharmatech have entered into an agreement to collaborate on the development of next-generation oral peptide drugs, the companies announced following a signing ceremony held at the LG Twin Towers in Yeouido, Seoul.
AviadoBio has extended its exclusive licence agreement with King’s College London to apply the vMiX RNAi gene-silencing platform across all human therapeutic areas.
The new initiative is intended to improve the global oversight of medical devices, AI, and innovative medicines and to streamline knowledge sharing efforts.
Alkermes has received ODD from both the FDA and the EC for alixorexton, its investigational OX2R agonist to treat idiopathic hypersomnia and narcolepsy.
As biologics continue to transform the pharmaceutical landscape and drive the industry’s growth, the demands for high-performance vial systems are growing.
MSD has received approval from the FDA for both Keytruda and Keytruda Qlex, in combination with Welireg, as an adjuvant treatment for adults with renal ccRCC.
In April 2026, Canada’s Drug Agency released an expanded data set offering insights within its regulatory system for drug approvals and reimbursement in Canada.
Peptide drug conjugates (PDCs) are attracting growing attention across the pharmaceutical sector as companies search for more specialised approaches to cancer treatment.
Roche has received the FDA priority review for its sBLA for adjuvant Tecentriq and Tecentriq Hybreza in combination with chemotherapy for colon cancer.
As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed to restore regulatory T-cell function and dampen neuroinflammation, through a pivotal stage of development in ALS.
Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies.
If enacted, BINSA would give lawmakers the right to monitor and restrict American companies from signing biotech and pharma-focused deals with Chinese entities.
